Antibody-Drug Conjugates (ADCs) have proven to be highly effective in cancer treatment, but their manufacturing poses challenges due to the specialized capabilities required. Discover how a CDMO partner with expertise and integrated manufacturing capabilities can help bring these innovative treatments to patients safely and efficiently.
Bispecific antibodies (bsAbs) are revolutionizing medicine by targeting two disease mechanisms simultaneously. However, the intricate structure of bsAbs presents a significant roadblock in their development and manufacturing. Learn how an innovative platform offers excellent pairing and significantly enhances productivity and quality.
An experienced contract manufacturer can help drug developers to better utilize valuable internal resources, leverage a deep pool of industry experience, and mitigate risk across development cycles — staying competitive in a rapidly evolving market. However, finding the right combination of services, culture, expertise, and capacity is critical.
Samsung Biologics is a fully integrated, end-to-end CDMO service provider offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish for biologics. Our facilities are cGMP compliant with bioreactor sizes ranging from small to large scale, enabling us to better serve the various needs of our clients and to meet growing biomanufacturing demands.
